References
- Nakayama M, Suzuki M, Inagaki A, Takemura K, Watanabe N, Tanigawa T, et al. Impaired quality of sleep in Ménière's disease patients. J Clin Sleep Med 2010;6:445–9.
- Tanigawa T, Tamaki T, Yamamuro O, Tanaka H, Nonoyama H, Shiga A, et al. Visualization of endolymphatic hydrops after administration of a standard dose of an intravenous gadolinium-based contrast agent. Acta Otolaryngol 2011;131:596–601.
- Yamakawa K. Uber die pathologische Veranderung bei einem Meniere Kranken. J. Otorhinolaryngol Soc Jpn 1938;44:2310–12.
- Hallpike CS, Cairns H. Observations on the pathology of Meniere’s syndrome. J Laryngol Otol 1938;53:625–55.
- Nakashima T, Naganawa S, Sugiura M, Teranishi M, Sone M, Hayashi H, et al. Visualization of endolymphatic hydrops in patients with Meniere's disease. Laryngoscope 2007;117:415–20.
- Katahira N, Tanigawa T, Tanaka H, Nonoyama H, Ueda H. Diluted gadoteridol (ProHance®) causes mild ototoxicity in cochlear outer hair cells. Acta Otolaryngol 2013;133:788–95.
- US Food and Drug Administration. Public health advisory: gadolinium containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Rockville, MD: FDA; 2006.
- Birka M, Wentker KS, Lusmöller E, Arheilger B, Wehe CA, Sperling M, et al. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem 2015;17:3321–8.
- Yamazaki M, Naganawa S, Kawai H, Sone M, Nakashima T. Gadolinium distribution in cochlear perilymph: differences between intratympanic and intravenous gadolinium injection. Neuroradiology 2012;54:1161–9.
- Kimitsuki T, Nakagawa T, Hisashi K, Komune S, Komiyama S. Gadolinium blocks mechano-electric transducer current in chick cochlear hair cells. Hear Res 1996;101:75–80.
- Tanaka H, Tanigawa T, Suzuki M, Otsuka K, Inafuku S. Effects of MRI contrast agents (Omniscan) on vestibular end organs. Acta Otolaryngol 2010;130:17–24.
- Runge VM, Ai T, Hao D, Hu X. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol 2011;46:807–16.
- Saliba I, El Fata F. Is intratympanic injection of erdosteine protective against cisplatin-induced ototoxicity? Neurotox Res 2012;21:302–8.
- Tanigawa T, Shibata R, Ouchi N, Kondo K, Ishii M, Katahira N, et al. Adiponectin deficiency exacerbates age-related hearing impairment. Cell Death Dis 2014;5:e1189.
- Murashita H, Tabuchi K, Hoshino T, Tsuji S, Hara A. The effects of tempol, 3-aminobenzamide and nitric oxide synthase inhibitors on acoustic injury of the mouse cochlea. Hear Res 2006;214:1–6.
- Duan M, Bjelke B, Fridberger A, Counter SA, Klason T, Skjönsberg A, et al. Imaging of the guinea pig cochlea following round window gadolinium application. Neuroreport 2004;15:1927–30.
- Kakigi A, Nishimura M, Takeda T, Okada T, Murata Y, Ogawa Y. Effects of gadolinium injected into the middle ear on the stria vascularis. Acta Otolaryngol 2008;128:841–5.
- Louza JP, Flatz W, Krause E, Gürkov R. Short-term audiologic effect of intratympanic gadolinium contrast agent application in patients with Ménière’s disease. Am J Otolaryngol 2012;33:533–7.
- Louza J, Krause E, Gürkov R. Hearing function after intratympanic application of gadolinium-based contrast agent: a long-term evaluation. Laryngoscope 2015;125:2366–70.
- Morizono T. Safety of antimicrobial applied in the middle ear cavity. Pract Otol (Kyoto) 2002;95:663–9.